Revision 1

#3351 Store at -20C

CD79A Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB, IF-IC	H	Endogenous	45-55	Rabbit	#P11912	973

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunofluorescence (Immunocytochemistry)	1:100

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

CD79A Antibody detects endogenous levels of total CD79A protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn217 of human CD79A. Antibodies are purified by peptide affinity chromatography

Background

Antigen receptors found on the surface of B cells contain a heterodimeric signaling component composed of CD79A and CD79B, also known as Ig α and Ig β, respectively (1,2). Presence of this receptor complex is essential for B cell development and function (3). Together these two proteins and the associated B cell receptor (BCR) initiate intracellular signaling following antigen binding (4,5). An immunoreceptor tyrosine-based activation motif (ITAM) found in the CD79A intracellular region appears to be important for its function (6). Antigen binding precedes formation of the CD79A and CD79B heterodimer and subsequent activation of receptor associated kinases (7). Research has shown that CD79A is a marker for B-lineage lymphoblastic leukemia (8). Additionally, investigators have found that mutations in the *CD79A* (*MB1*) gene are associated with abnormally low levels of functional B cell receptors in some cases of chronic B cell lymphocytic leukemia (9).

Background References

1. van Noesel, C.J. et al. (1991) *J Immunol* 146, 3881-8.
2. Minegishi, Y. et al. (1999) *J Clin Invest* 104, 1115-21.
3. Yu, L.M. and Chang, T.W. (1992) *J Immunol* 148, 633-7.
4. Storch, B. et al. (2007) *Eur J Immunol* 37, 252-60.
5. Mason, D.Y. et al. (1995) *Blood* 86, 1453-9.
6. Luisiri, P. et al. (1996) *J Biol Chem* 271, 5158-63.
7. Pike, K.A. et al. (2004) *J Immunol* 172, 2210-8.
8. Astsaturov, I.A. et al. (1996) *Leukemia* 10, 769-73.
9. Vuillier, F. et al. (2005) *Blood* 105, 2933-40.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting **IF-IC:** Immunofluorescence (Immunocytochemistry)

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
X: Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
GP: Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.